Regenicin, Inc. is a clinical-stage biotechnology company dedicated to the development of peptide-based therapeutics designed to promote tissue repair, modulate inflammation and enhance immune function. The company’s proprietary platform focuses on small synthetic peptides that mimic naturally occurring proteins involved in cell signaling and wound healing. Regenicin’s lead candidates target serious unmet medical needs in ophthalmology, trauma care and infectious disease, positioning the company at the intersection of regenerative medicine and immunotherapy.
One of Regenicin’s flagship programs is RGN-259, a topical formulation of a synthetic analog of thymosin beta-4. RGN-259 has been evaluated in multiple clinical trials for the treatment of severe ocular surface disorders, including persistent epithelial defects, neurotrophic keratitis and dry eye disease. By promoting cell migration, differentiation and angiogenesis, RGN-259 aims to accelerate corneal healing and reduce chronic inflammation. The company has conducted Phase 2 and Phase 3 studies in the United States, with additional investigator-sponsored trials underway in Europe and Latin America.
Beyond ophthalmology, Regenicin is advancing TTHX1114, a next-generation peptide engineered to prevent and treat pulmonary infections and sepsis in high-risk patient populations. Preclinical models have demonstrated that TTHX1114 can reduce bacterial load in the lungs, enhance tissue repair and improve survival rates in animal subjects challenged with pathogens commonly associated with hospital-acquired pneumonia. The company is exploring strategic collaborations to support IND-enabling studies and is engaging regulatory authorities to define clinical pathways for both human and veterinary applications.
Headquartered in South Florida, Regenicin was founded in 2009 and is led by CEO Steven Rosenfeld, a biotechnology industry veteran with more than three decades of experience in drug development and corporate leadership. The company’s research efforts are supported by a network of academic and contract research organizations across North America and Europe. As Regenicin advances its pipeline toward commercialization, it continues to seek partnerships and licensing opportunities to bring its novel peptide therapies to patients worldwide.
AI Generated. May Contain Errors.
Free RGIN Stock Alerts